Mice lacking the extracellular matrix protein tenascin-C showed a reduced ability to repair muscular damage compared to controls.

Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.

Transformative Growth Ahead for Immunotherapy Drugs as Precision Medicine, AI, and Biologics Propel Market Innovation and ...

Alexandria Real Estate Equities, Inc. ( ARE) Analyst/Investor Day December 3, 2025 8:30 AM EST Good morning, everyone, and thank you to those joining us in person and via webcast for Alexandria Real ...